Suggested remit: To appraise the clinical and cost effectiveness of zanubrutinib within its marketing authorisation for tresting relapsed or refractory mantle cell lymphoma.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6392

Provisional Schedule

Committee meeting 11 June 2025
Expected publication 20 August 2025

Project Team

Project lead Leena Issa

Email enquiries

External Assessment Group Warwick Evidence, Warwick Medical School, University of Warwick

Stakeholders

Companies sponsors BeiGene (zanubrutinib)
Others Department of Health and Social Care
  NHS England
Patient carer groups Lymphoma Action
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
Associated public health groups None
Comparator companies Accord (bendamustine, cytarabine, doxorubicin) – confidentiality agreement not signed, not participating
  Alliance Healthcare (cyclophosphamide, cytarabine) – confidentiality agreement not signed, not participating
  Baxter Healthcare (cyclophosphamide, doxorubicin) – confidentiality agreement not signed, not participating
  Celltrion Healthcare (rituximab) – confidentiality agreement not signed, not participating
  Consilient Health (bendamustine) – confidentiality agreement not signed, not participating
  Dr. Reddy's Laboratories (bendamustine) – confidentiality agreement not signed, not participating
  Gilead Sciences (brexucabtagene autoleucel) – confidentiality agreement signed, participating
  Hospira UK (cytarabine, vincristine) – confidentiality agreement not signed, not participating
  Jazz Pharmaceuticals (cytarabine) – confidentiality agreement not signed, not participating
  Johnson & Johnson Innovative Medicine (ibrutinib) – confidentiality agreement signed, participating
  medac GmbH (doxorubicin) – confidentiality agreement not signed, not participating
  Pfizer (cytarabine, doxorubicin, rituximab, vincristine) – confidentiality agreement signed, participating
  Roche Products (rituximab) – confidentiality agreement signed, participating
  Sandoz (cyclophosphamide, rituximab) – confidentiality agreement not signed, not participating
  Seacross Pharmaceuticals (bendamustine, doxorubicin) – confidentiality agreement not signed, not participating
  Teva UK (vincristine) – confidentiality agreement not signed, not participating
  Zentiva (bendamustine) – confidentiality agreement not signed, not participating
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health - Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  NHS Wales Joint Commissioning Committee
  Scottish Medicines Consortium
  Welsh Government
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
12 December 2024 Referral
29 October 2024 Invitation to participate
23 July 2024 - 20 August 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6392
23 July 2024 Scoping commenced.
19 March 2024 In progress. Topic in progress
21 December 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected
14 December 2023 Topic selection

For further information on our processes and methods, please see our CHTE processes and methods manual